CORRECTED-Aurora Cannabis Q2 revenue beats estimates on 15% medical cannabis growth

Overview

• Aurora fiscal Q2 2026 revenue beats analyst expectations due to 15% growth in medical cannabis

• Adjusted EBITDA for fiscal Q2 2026 grows 52% to C$15.4 mln

• Company maintains strong balance sheet with C$141.9 mln cash, debt-free cannabis business

Outlook

• Aurora expects Q3 2026 net revenue to grow, driven by 8%-12% increase in Global Medical Cannabis

• Company anticipates positive free cash flow in Q3 2026 due to improved operating cash use

• Aurora expects strong adjusted gross margins in cannabis business for Q3 2026

Result Drivers

• MEDICAL CANNABIS GROWTH - 15% YoY increase in medical cannabis revenue driven by sales in Australia, Germany, Poland, and the UK

• CONSUMER CANNABIS DECLINE - Decrease in consumer cannabis revenue due to focus on higher-margin medical products

• PLANT PROPAGATION REVENUE - 34% increase in plant propagation revenue from organic growth and expanded offerings

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Aurora Cannabis Inc is C$7.85, about 18.2% above its November 4 closing price of C$6.42

• The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nCNWW4hXFa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.